Grant: CIHR Fellowship
University of Toronto
$135,000.00
The mechanism of ADAR1 in regulating cancer immune evasion
EF 2020-21
Résumé
The immune system protects the body against infectious diseases, as well as inherent diseases such as cancer. The immune system is the first line of defense charged to eliminate cancer cells from the body. However, cancer has evolved mechanisms to evade the immune system, some of which have been exposed and leveraged with powerful immunotherapies. Despite the incredible advances made with new immunotherapies in the past two decades, the majority of cancers remain refractory to immunotherapy through intrinsic and acquired genetic and/or epigenetic mechanisms of resistance. Our understanding of the genes and pathways that program cancer cells to evade the immune system is very limited. In other words, the inventory of secret weapons that cancer cells harbour against the immune system still needs to be fully catalogued. Identifying cancer intrinsic immune invasion genes and the mechanism of action by which these genes help cancer cells evade the immune system will uncover the Achilles heel of cancer and find new ways to weaken cancers against the immune system and immunotherapy. Using state-of-the-art technologies in genetics including systematic genome-wide CRISPR screening, as well as a cutting edge cost-effective single-cell sequencing approach, our lab has identified key genes that help cancer cells evade tumor infiltrating immune cells. One such gene is Adar, which helps cancer cells resist the immune system. It is currently not known how the Adar gene contributes to resistance to immunotherapy; however, preliminary results by our group and others suggest that Adar is involved in innate immunity. The goal of my project is to study how ADAR regulates cancer immune evasion and which molecular pathways synergize with ADAR activity to enhance immunotherapy. In this project, in collaboration with Agios pharmaceuticals company, we also aim to translate our findings to clinical medicine by developing new anti-cancer treatments based on targeting ADAR-mediated pathways.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
441367
Name
Nami Babak
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
The mechanism of ADAR1 in regulating cancer immune evasion
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Adar1; Cancer; Crispr/Cas9; Genetics; Genomics; Immune Resistance; Immune System; Immunotherapy
Abstract
The immune system protects the body against infectious diseases, as well as inherent diseases such as cancer. The immune system is the first line of defense charged to eliminate cancer cells from the body. However, cancer has evolved mechanisms to evade the immune system, some of which have been exposed and leveraged with powerful immunotherapies. Despite the incredible advances made with new immunotherapies in the past two decades, the majority of cancers remain refractory to immunotherapy through intrinsic and acquired genetic and/or epigenetic mechanisms of resistance. Our understanding of the genes and pathways that program cancer cells to evade the immune system is very limited. In other words, the inventory of secret weapons that cancer cells harbour against the immune system still needs to be fully catalogued. Identifying cancer intrinsic immune invasion genes and the mechanism of action by which these genes help cancer cells evade the immune system will uncover the Achilles heel of cancer and find new ways to weaken cancers against the immune system and immunotherapy. Using state-of-the-art technologies in genetics including systematic genome-wide CRISPR screening, as well as a cutting edge cost-effective single-cell sequencing approach, our lab has identified key genes that help cancer cells evade tumor infiltrating immune cells. One such gene is Adar, which helps cancer cells resist the immune system. It is currently not known how the Adar gene contributes to resistance to immunotherapy; however, preliminary results by our group and others suggest that Adar is involved in innate immunity. The goal of my project is to study how ADAR regulates cancer immune evasion and which molecular pathways synergize with ADAR activity to enhance immunotherapy. In this project, in collaboration with Agios pharmaceuticals company, we also aim to translate our findings to clinical medicine by developing new anti-cancer treatments based on targeting ADAR-mediated pathways.
Competitiondate
202012
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Nami, Babak
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~